Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
20.7M
-
Shares change
-
+615K
-
Total reported value, excl. options
-
$15.4M
-
Value change
-
-$13.8M
-
Put/Call ratio
-
0.9
-
Number of buys
-
28
-
Number of sells
-
-57
-
Price
-
$0.74
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q2 2022
100 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.7M shares
of 55.7M outstanding shares and own 37.22% of the company stock.
Largest 10 shareholders include Aquilo Capital Management, LLC (5.32M shares), BVF INC/IL (3.09M shares), Atlas Venture Associates IX, LLC (1.38M shares), VANGUARD GROUP INC (1.25M shares), Atlas Venture Life Science Advisors, LLC (1.03M shares), RENAISSANCE TECHNOLOGIES LLC (939K shares), Alphabet Inc. (890K shares), Rock Springs Capital Management LP (771K shares), BlackRock Inc. (690K shares), and D. E. Shaw & Co., Inc. (649K shares).
This table shows the top 57 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.